MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Sargent Investment Group LLC

Sargent Investment Group LLC boosted its holdings in MediWound Ltd. (NASDAQ:MDWDFree Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 121,190 shares of the biopharmaceutical company’s stock after acquiring an additional 3,998 shares during the period. Sargent Investment Group LLC owned 1.12% of MediWound worth $2,217,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of MediWound in the 4th quarter valued at about $32,000. MetLife Investment Management LLC acquired a new position in MediWound in the third quarter worth $89,000. Barclays PLC grew its position in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 8,449 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of MediWound during the third quarter valued at approximately $212,000. Finally, State Street Corp increased its position in MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after buying an additional 45,529 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Stock Performance

Shares of MediWound stock opened at $19.50 on Wednesday. The company’s fifty day simple moving average is $17.96 and its 200-day simple moving average is $17.75. MediWound Ltd. has a 1 year low of $11.04 and a 1 year high of $24.00.

MediWound (NASDAQ:MDWDGet Free Report) last announced its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period last year, the business posted ($0.24) earnings per share. Equities analysts forecast that MediWound Ltd. will post -2.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of MediWound in a research report on Friday, January 10th.

View Our Latest Research Report on MDWD

MediWound Profile

(Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Read More

Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWDFree Report).

Institutional Ownership by Quarter for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.